Although further efforts are needed to fully report annual bleeding rates and long-term complications and to evaluate quality of care in women with hemophilia and carriers, the adoption of standards that address symptom recognition is warranted, acknowledging for example that women can experience joint bleeds and pain due to arthropathy, and investigating the possibility of an increased risk of low BMD due to low FVIII or FIX levels. This evidence concerns the gene F8 and hemophilia.